首页> 外文期刊>Hormones: International Journal of Endocrinology and Metabolism >Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis
【24h】

Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis

机译:低风险的甲状腺乳头状甲状腺癌患者,在不进行预防性中央室淋巴结清扫的情况下,行全甲状腺切除术,并用小剂量50mCi RAI消融,预后良好

获取原文
           

摘要

BACKGROUND: The current trend in the management of low risk differentiated thyroid carcinoma is to follow less aggressive strategies. Objective: To assess the long-term morbidity and mortality outcomes of low-risk papillary thyroid carcinoma (PTC) patients undergoing minimal intervention. DESIGN: We retrospectively analyzed 137 patients with low-risk PTC (stage I: n=77; stage II: n=60). Of these patients, 107 (Group 1) had macro-PTC and underwent near-total thyroidectomy and received postoperatively 50mCi RAI. The remaining 30 patients (Group 2) had micro-PTC (1cm) and were treated only by means of near-total thyroidectomy. RESULTS: The median follow-up for Group 1 patients was 10 years (range: 3-30). At 1-year evaluation, 8 patients of Group 1 had indeterminate or incomplete biochemical response, of whom 4 had also incomplete structural response to initial therapy. Only 1 of 4 patients with structural incomplete response underwent cervical lymph node dissection and then received an additional dose of 100mCi RAI. The remaining 7 patients received only an additional dose of 100mCi RAI. These patients have been continuously followed till the present time with no recurrences or deaths (median follow-up: 17.5 years; 3-30 years). At 15 years, 2 patients of Group 1 experienced biochemical recurrence and they received 100mCi RAI. Three patients of Group 2 experienced recurrence, with 2 receiving 50mCi RAI and 1 undergoing cervical lymph node dissection with 50mCi RAI. CONCLUSIONS: Patients with low-risk macro-PTC treated by means of near-total thyroidectomy without PCCLND and receiving postoperatively a low dose of 50mCi RAI have excellent long-term prognosis.
机译:背景:低风险分化型甲状腺癌的当前治疗趋势是采取较不积极的策略。目的:评估接受最少干预的低风险乳头状甲状腺癌(PTC)患者的长期发病率和死亡率。设计:我们回顾性分析了137例低危PTC患者(I期:n = 77; II期:n = 60)。在这些患者中,有107例(第1组)进行了宏观PTC并接受了近全甲状腺切除术,术后接受了50mCi RAI。其余30例患者(第2组)患有微型PTC(<1厘米),仅通过近全甲状腺切除术进行治疗。结果:第1组患者的中位随访时间为10年(范围:3-30)。在1年评估中,第1组的8名患者生化反应不确定或不完全,其中4例对初始治疗的结构反应也不完全。在结构不完全反应的4位患者中,只有1位接受了颈淋巴结清扫术,然后接受了100mCi RAI的额外剂量。其余7名患者仅接受了100mCi RAI的额外剂量。这些患者一直接受随访,直到目前为止均未复发或死亡(中位随访时间:17.5年; 3-30年)。 15岁时,第1组的2名患者经历了生化复发,并接受了100mCi RAI。第2组的3例患者复发,其中2例接受50mCi RAI的治疗,1例接受50mCi RAI的颈淋巴结清扫术。结论:通过不进行PCCLND的近全甲状腺切除术治疗低危型宏观PTC患者,术后接受低剂量50mCi RAI的患者具有良好的长期预后。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号